MedTrace Logo

Trans-resveratrol's Influence on the Development of CHF in Early Postmenopausal Women with HTN and Reduced BMD

NCT06828211 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2025-03-19

No results posted yet for this study

Summary

1. To measure the ability of trans-resveratrol to influence the development of chronic heart failure (CHF) in women in the early postmenopausal period (1-4 years) with hypertension (HTN) and reduced bone mineral density (BMD).
2. To evaluate the safety of long-term use of trans-resveratrol in an amount of 500 mg per day.
3. To develop modern measures to influence the development of CHF in women of this group

Conditions

Interventions

DIETARY_SUPPLEMENT

Trans-resveratrol extract from Polygonum Cuspidatum

Trans-resveratrol extract from Polygonum Cuspidatum

OTHER

Placebo

Placebo

Sponsors & Collaborators

  • OMNIFARMA LLC

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
45 Years
Max Age
55 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-09-09
Primary Completion
2025-02-09
Completion
2025-03-31

Countries

  • Ukraine

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06828211 on ClinicalTrials.gov